Cargando…

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19 vaccines, and small-molecule antivirals can provide an important therapeutic treatment option. The viral main protease (M(pro)) is critical for virus replication and thus is considered an attractive drug target. We perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kneller, Daniel W., Li, Hui, Phillips, Gwyndalyn, Weiss, Kevin L., Zhang, Qiu, Arnould, Mark A., Jonsson, Colleen B., Surendranathan, Surekha, Parvathareddy, Jyothi, Blakeley, Matthew P., Coates, Leighton, Louis, John M., Bonnesen, Peter V., Kovalevsky, Andrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046211/ https://www.ncbi.nlm.nih.gov/pubmed/35477935 http://dx.doi.org/10.1038/s41467-022-29915-z

Ejemplares similares

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity
por: Kneller, Daniel, et al.
Publicado: (2022)

Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography
por: Kneller, Daniel W., et al.
Publicado: (2021)

Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023)

Unusual zwitterionic catalytic site of SARS–CoV-2 main protease revealed by neutron crystallography
por: Kneller, Daniel W., et al.
Publicado: (2020)

Room-temperature neutron and X-ray data collection of 3CL M(pro) from SARS-CoV-2
por: Kneller, Daniel W., et al.
Publicado: (2020)

Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography
por: Kneller, Daniel W., et al.
Publicado: (2021)

Insights into the mechanism of SARS-CoV-2 main protease autocatalytic maturation from model precursors
por: Aniana, Annie, et al.
Publicado: (2023)

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir
por: Bai, Yu, et al.
Publicado: (2021)

Unmasking the Conformational Stability and Inhibitor Binding to SARS-CoV-2 Main Protease Active Site Mutants and Miniprecursor
por: Kovalevsky, Andrey, et al.
Publicado: (2022)

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022)

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022)

Malleability of the SARS-CoV-2 3CL M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals
por: Kneller, Daniel W., et al.
Publicado: (2020)

Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain
por: Nashed, Nashaat T., et al.
Publicado: (2022)

Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL M(pro): insights into enzyme mechanism and drug design
por: Kneller, Daniel W., et al.
Publicado: (2020)

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
por: Sanders, Brian C., et al.
Publicado: (2023)

Structural plasticity of SARS-CoV-2 3CL M(pro) active site cavity revealed by room temperature X-ray crystallography
por: Kneller, Daniel W., et al.
Publicado: (2020)

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
por: Alugubelli, Yugendar R., et al.
Publicado: (2022)

Boceprevir
Publicado: (2012)

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022)

Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor
por: Glaser, Jens, et al.
Publicado: (2022)

Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease
por: Pavlova, Anna, et al.
Publicado: (2020)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis
por: Isakov, V., et al.
Publicado: (2016)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: A virtual screening approach
por: Borkotoky, Subhomoi, et al.
Publicado: (2021)

Boceprevir-induced Herpes Zoster
por: Babalı, Ayşegul, et al.
Publicado: (2018)

A suitable drug structure for interaction with SARS‐CoV‐2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study
por: Yoosefian, Mehdi, et al.
Publicado: (2023)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
por: Xia, Zilei, et al.
Publicado: (2021)

Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19
por: Bocci, Giovanni, et al.
Publicado: (2020)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and X-ray diffraction at room temperature
por: Correy, Galen J., et al.
Publicado: (2022)

The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature
por: Correy, Galen J., et al.
Publicado: (2022)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Supercomputer simulation of the covalent inhibition of the main protease of SARS-CoV-2
por: Nemukhin, A. V., et al.
Publicado: (2022)

Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide
por: Yamane, Daiki, et al.
Publicado: (2022)

Boceprevir and personalized medicine in hepatitis C virus infection
por: Habersetzer, François, et al.
Publicado: (2012)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cu586d75k91kot9m89u8ba480b